Menopause hormone therapy (MHT) demonstrates measurable effects on body composition during the hormonal transition, specifically attenuating central fat accumulation and preserving lean body mass through estrogen replacement. Meta-analyses of randomized trials confirm these compositional benefits occur independent of chronological aging effects. The hormonal decline during menopause drives visceral adipose tissue expansion and muscle mass reduction—changes that MHT can partially counteract through restored estrogen signaling.
This finding illuminates a nuanced distinction often missed in clinical practice: body composition versus weight loss represent different therapeutic targets. While MHT addresses the underlying hormonal driver of menopausal fat redistribution, it lacks efficacy as a primary obesity intervention. The emerging observational data suggesting synergy between MHT and GLP-1 obesity medications remains preliminary and confounded. For the millions of women navigating menopause, this clarifies MHT's role as a symptom-management tool with compositional benefits rather than a weight-loss strategy. The research reinforces evidence-based prescribing: MHT for established indications like vasomotor symptoms, with body composition improvements as a secondary benefit rather than a primary goal.